Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction.
- Author:
Qiaoyun CHEN
1
;
Nan WANG
;
Feng YAO
;
Xiaohe LU
Author Information
1. Department of Pharmacy, Nanjing General Hospital of Nanjing Command, Nanjing, Jiangsu 210002, China.
- Publication Type:Journal Article
- MeSH:
3',5'-Cyclic-GMP Phosphodiesterases;
Cyclic Nucleotide Phosphodiesterases, Type 5;
Erectile Dysfunction;
drug therapy;
Humans;
Male;
Phosphodiesterase Inhibitors;
adverse effects;
pharmacokinetics;
therapeutic use;
Phosphoric Diester Hydrolases;
physiology;
Piperazines;
therapeutic use;
Purines;
Sildenafil Citrate;
Sulfones
- From:
National Journal of Andrology
2004;10(4):302-304
- CountryChina
- Language:Chinese
-
Abstract:
Since the introduction of the phosphodiesterase type 5 (PDE-5) inhibitor sildenafil in 1998, there has been a fundamental change in the treatment of erectile dysfunction (ED). Sildenafil has already been used by over 20 million men in over 100 countries, with a death rate similar to that of general population. The success rate of sildenafil amounts to an average of over 80%, and sildenafil has become the first choice for patients with ED. The development of two new PDE-5 inhibitors, vardenafil and tadalafil, has added to the options for the treatment of ED. In this review, a comparison is made of the pharmcodynamics, pharmacokinetics and adverse reactions between the three PDE-5 inhibitors to assess their efficacy and safety.
